Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PLA2G2A siRNA
- Development stage
- Preclinical
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Parenteral
01
Overview
PLA2G2A siRNA is a research-grade small interfering RNA (siRNA) reagent designed to silence the expression of the *PLA2G2A* gene, which encodes Phospholipase A2 Group IIA. This enzyme is a secretory calcium-dependent phospholipase involved in inflammatory responses, lipid metabolism, and host defense. In oncological research, particularly in pancreatic and prostate cancers, PLA2G2A siRNA is used to investigate the role of the target in fatty acid synthesis, energy metabolism, and resistance to ferroptosis. It is primarily available as a laboratory tool from various life science suppliers and is not currently being developed as a therapeutic asset by a specific pharmaceutical company.
- Brand names
- ON-TARGETplus SMARTpoolSilencer SelectStealth siRNA
- Other names
- Phospholipase A2 Group IIA siRNAPLA2G2A small interfering RNAPLA-2G2A small interfering RNAPLA 2G2A small interfering RNA
02
Targets
PLA2G2A (Secretory phospholipase A2 group IIA)
Beyond the preview
Go deeper on PLA2G2A siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PLA2G2A siRNA.